van Zoelen Everardus J, Duarte Isabel, Hendriks José M, van der Woning Sebastian P
Department of Cell and Applied Biology, Faculty of Science, Radboud University Nijmegen, PO Box 9010, 6500 GL, Nijmegen, The Netherlands.
Present Address: Department of Cell and Applied Biology, Radboud University Nijmegen, Heyendaalseweg 135, 6525 AJ, Nijmegen, The Netherlands.
Stem Cell Res Ther. 2016 Aug 26;7(1):123. doi: 10.1186/s13287-016-0375-3.
Patients suffering from osteoporosis show an increased number of adipocytes in their bone marrow, concomitant with a reduction in the pool of human mesenchymal stem cells (hMSCs) that are able to differentiate into osteoblasts, thus leading to suppressed osteogenesis.
In order to be able to interfere with this process, we have investigated in-vitro culture conditions whereby adipogenic differentiation of hMSCs is impaired and osteogenic differentiation is promoted. By means of gene expression microarray analysis, we have investigated genes which are potential targets for prevention of fat cell differentiation.
Our data show that BMP2 promotes both adipogenic and osteogenic differentiation of hMSCs, while transforming growth factor beta (TGFβ) inhibits differentiation into both lineages. However, when cells are cultured under adipogenic differentiation conditions, which contain cAMP-enhancing agents such as IBMX of PGE2, TGFβ promotes osteogenic differentiation, while at the same time inhibiting adipogenic differentiation. Gene expression and immunoblot analysis indicated that IBMX-induced suppression of HDAC5 levels plays an important role in the inhibitory effect of TGFβ on osteogenic differentiation. By means of gene expression microarray analysis, we have investigated genes which are downregulated by TGFβ under adipogenic differentiation conditions and may therefore be potential targets for prevention of fat cell differentiation. We thus identified nine genes for which FDA-approved drugs are available. Our results show that drugs directed against the nuclear hormone receptor PPARG, the metalloproteinase ADAMTS5, and the aldo-keto reductase AKR1B10 inhibit adipogenic differentiation in a dose-dependent manner, although in contrast to TGFβ they do not appear to promote osteogenic differentiation.
The approach chosen in this study has resulted in the identification of new targets for inhibition of fat cell differentiation, which may not only be relevant for prevention of osteoporosis, but also of obesity.
骨质疏松症患者的骨髓中脂肪细胞数量增加,同时能够分化为成骨细胞的人间充质干细胞(hMSCs)池减少,从而导致成骨作用受到抑制。
为了能够干预这一过程,我们研究了体外培养条件,在此条件下hMSCs的脂肪生成分化受到损害,而成骨分化得到促进。通过基因表达微阵列分析,我们研究了作为预防脂肪细胞分化潜在靶点的基因。
我们的数据表明,骨形态发生蛋白2(BMP2)促进hMSCs的脂肪生成和成骨分化,而转化生长因子β(TGFβ)抑制向这两个谱系的分化。然而,当细胞在含有cAMP增强剂(如异丁基甲基黄嘌呤(IBMX)或前列腺素E2(PGE2))的脂肪生成分化条件下培养时,TGFβ促进成骨分化,同时抑制脂肪生成分化。基因表达和免疫印迹分析表明,IBMX诱导的组蛋白去乙酰化酶5(HDAC5)水平的抑制在TGFβ对成骨分化的抑制作用中起重要作用。通过基因表达微阵列分析,我们研究了在脂肪生成分化条件下被TGFβ下调的基因,因此这些基因可能是预防脂肪细胞分化的潜在靶点。我们由此鉴定出9个有FDA批准药物可用的基因。我们的结果表明,针对核激素受体过氧化物酶体增殖物激活受体γ(PPARG)、金属蛋白酶含血小板凝血酶敏感蛋白基序的解聚素样金属蛋白酶5(ADAMTS5)和醛糖酮还原酶1B10(AKR1B10)的药物以剂量依赖的方式抑制脂肪生成分化,尽管与TGFβ不同,它们似乎不促进成骨分化。
本研究中采用的方法已导致鉴定出抑制脂肪细胞分化的新靶点,这可能不仅与预防骨质疏松症有关,而且与预防肥胖症有关。